Journal of cancer research and clinical oncology
-
J. Cancer Res. Clin. Oncol. · Jul 2013
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.
Trastuzumab and chemotherapy is the current standard of care in HER2+ early or locally advanced breast cancer, but there are scanty literature data of its real world effectiveness. ⋯ Our data set the relevance of molecular subclasses and residual tumor burden after neoadjuvant as the most relevant prognostic factors for survival in this cohort of patients.
-
J. Cancer Res. Clin. Oncol. · Jul 2013
Meta AnalysisHigh circulating VEGF level predicts poor overall survival in lung cancer.
Vascular endothelial growth factor (VEGF) is considered as the best-validated key regulator of angiogenesis, while the prognostic role of circulating VEGF in lung cancer remains controversial. We conducted a meta-analysis to evaluate the prognostic role of circulating VEGF. ⋯ Our results indicate that high level of circulating VEGF predicts poor OS in lung cancer, yet it does not predict poor PFS.